We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+42.89%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$4.69B
AUM Growth
+$937M
(+25%)
Cap. Flow
+$184M
Cap. Flow
% of AUM
3.93%
Top 10 Holdings %
Top 10 Hldgs %
46.5%
Holding
101
New
13
Increased
10
Reduced
7
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Legend Biotech
LEGN
|
+$110M |
| 2 |
THRD
Third Harmonic Bio
THRD
|
+$62.6M |
| 3 |
Cogent Biosciences
COGT
|
+$55M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$50.1M |
| 5 |
Biogen
BIIB
|
+$44.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Veru
VERU
|
+$89.3M |
| 2 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
+$61.3M |
| 3 |
Natera
NTRA
|
+$46.4M |
| 4 |
Dyne Therapeutics
DYN
|
+$19.3M |
| 5 |
Guardant Health
GH
|
+$19.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.68% |
| 2 | Financials | 0.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$16.5B
| $781M | 16.67% |
7,567,900
| – | – |
|
|
2
Biogen
BIIB
$30.9B
| $250M | 5.34% |
937,549
+210,525
| +29% | +$44.7M |
|
3
Cytek Biosciences
CTKB
$566M
| $197M | 4.2% |
13,381,054
| – | – |
|
|
FMTX
4
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $180M | 3.84% |
9,011,651
| – | – |
|
|
DAWN
5
DELISTED
Day One Biopharmaceuticals
DAWN
| $141M | 3.01% |
7,040,622
| – | – |
|
|
JBIO
6
Jade Biosciences
JBIO
$1.18B
| $137M | 2.92% |
236,114
| – | – |
|
7
Rhythm Pharmaceuticals
RYTM
$7.31B
| $134M | 2.86% |
5,471,067
+600,000
| +12% | +$11.2M |
|
8
Travere Therapeutics
TVTX
$5.17B
| $121M | 2.59% |
4,922,941
| – | – |
|
|
BLU
9
DELISTED
BELLUS Health Inc.
BLU
| $120M | 2.56% |
11,385,574
+1,155,300
| +11% | +$12.3M |
|
10
Janux Therapeutics
JANX
$912M
| $117M | 2.5% |
8,670,644
| – | – |
|
11
Vaxcyte
PCVX
$7.65B
| $110M | 2.35% |
4,581,203
| – | – |
|
|
DICE
12
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $106M | 2.25% |
5,208,911
| – | – |
|
|
IMGN
13
DELISTED
Immunogen Inc
IMGN
| $104M | 2.22% |
21,741,458
| – | – |
|
14
Nkarta
NKTX
$152M
| $103M | 2.19% |
7,805,129
| – | – |
|
15
Acumen Pharmaceuticals
ABOS
$152M
| $98M | 2.09% |
9,770,773
| – | – |
|
|
16
Legend Biotech
LEGN
$3.65B
| $95.4M | 2.04% |
+2,338,610
| New | +$110M |
|
|
ITOS
17
DELISTED
iTeos Therapeutics
ITOS
| $84.1M | 1.8% |
4,417,259
| – | – |
|
18
Relmada Therapeutics
RLMD
$540M
| $74M | 1.58% |
2,000,000
| – | – |
|
19
PepGen
PEPG
$118M
| $73.8M | 1.58% |
8,131,952
| – | – |
|
20
Geron
GERN
$898M
| $70.5M | 1.5% |
30,126,299
| – | – |
|
21
Aclaris Therapeutics
ACRS
$715M
| $69.2M | 1.48% |
4,398,453
| – | – |
|
|
THRD
22
DELISTED
Third Harmonic Bio
THRD
| $65.9M | 1.41% |
+3,475,687
| New | +$62.6M |
|
23
AN2 Therapeutics
ANTX
$181M
| $65.6M | 1.4% |
3,773,517
+25,128
| +0.7% | +$293K |
|
24
Tyra Biosciences
TYRA
$1.85B
| $63.6M | 1.36% |
7,236,454
| – | – |
|
25
Wave Life Sciences
WVE
$1.12B
| $62.1M | 1.32% |
17,202,009
| – | – |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, RA Capital Management held 101 positions worth $4.69B, up 25% from $3.75B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
RA Capital Management deployed $184M of net new capital in Q3 2022, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was Legend Biotech: 2,338,610 shares worth $95.4M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Concert Pharmaceuticals, Inc., an estimated $13.5M trimmed.
- RA Capital Management's largest Q3 2022 buy was Legend Biotech: 2,338,610 shares worth $95.4M.
- RA Capital Management added most to Biogen in Q3 2022, an estimated $44.7M increase.
- RA Capital Management's biggest Q3 2022 reduction was Concert Pharmaceuticals, Inc., cutting an estimated $13.5M.
- RA Capital Management fully exited Veru in Q3 2022, selling an estimated $89.3M.
- RA Capital Management's ten largest holdings make up 46% of its $4.69B portfolio in Q3 2022.
- RA Capital Management opened 13 new positions and closed 20 in Q3 2022.
- RA Capital Management's portfolio value rose 25% quarter-over-quarter to $4.69B.
Based on RA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.